We have developed the Rh-catalyzed selective C–H functionalization of 6-arylpurines, in
which the purine moiety directs the C–H bond activation of the aryl pendant. While the first C …

(57) ABSTRACT The present invention provides 1-[[[4-(4-fluoro-2-methyl 1H-indol-5-yl) oxy-
6-methoxyquinolin-7-yl] oxy] methyl] cy clopro-pylamine used for combating a tumor …

The present invention relates a new process to synthesize 1-([4-(4-Fluoro-2-methyl-1H-indol-
5-yloxy)-6-methoxy quinolin-7-yloxy) methyl) cyclopropanamine (AL3818). A stable …

The present application provides a quinoline derivative against non-small cell lung cancer. 1-
[[[4-(4-fluoro-2-methyl)-1H-indol-5-yl) oxy-6-methoxyquinolin-7-yl] oxy] methyl] …

US10183017B2 - Methods and uses of quinoline derivatives in the treatment of soft tissue
sarcomas and pharmaceutical compositions for treatment of same - Google Patents …

The present invention relates to the compounds of formula I, processes for their preparation,
pharmaceutical compositions containing them as active ingredient, methods for the …

Provided in the present invention is a quinoline derivative for treating gastric cancer. 1-[[[4-(4-
fluoro-2-methyl-1H-indol-5-yl) oxy-6-methoxyquinolin-7-yl] oxy] methyl] cyclopropylamine or …

Journal of Clinical Oncology (2009), vol. 27 (25), pp. 4169-4176. Han et al.,“Anlotinib as a
third-line therapy in patients with refractory advanced non-small-cell lung cancer: a …

1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy quinolin-7-yloxy) methyl)
cyclopropanamine (AL3818). A stable crystalline form of A13818 has been prepared. Salts …

The present invention provides a novel pyridine derivative, a pharmaceutically acceptable
salt thereof, a method for preparing the same, and a pharmaceutical composition con taining …